Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0HS92)

• Drug Name: Merimepodib Drug Info
• Synonyms: Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Gastric adenocarcinoma	2B72	Phase 3	[1]
Head and neck cancer	2D42	Phase 2	[1]
Hepatitis C virus infection	1E51.1	Patented	[2]
Hepatitis virus infection	1E50-1E51	Discontinued in Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 153241
  CAS Number: CAS 198821-22-6
  TTD Drug ID: DM0HS92

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[6]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[7]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[8]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[9]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[10]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[11]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[12]
Pertuzumab	DMHJV0X	Breast cancer	2C60-2C65	Approved	[13]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[14]
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[15]

Drug(s) Targeting Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mercaptopurine	DMTM2IK	Acute lymphoblastic leukaemia	2A85	Approved	[16]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[17]
Tiazofurin	DM5JWV9	Solid tumour/cancer	2A00-2F9Z	Approved	[18]
Mizoribine	DMW6F0S	Transplant rejection	NE84	Approved	[5]
Viramidine	DMJFNR9	Hepatitis C virus infection	1E51.1	Phase 3	[19]
VX-944	DME321B	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
VX-148	DML32R8	Psoriasis vulgaris	EA90	Patented	[20]
PMID28074661-Compound-US20100022547C81	DMM9E1U	N. A.	N. A.	Patented	[2]
PMID28074661-Compound-US20120264760C80	DM75QVW	N. A.	N. A.	Patented	[2]
Carbamide derivative 9	DMY06VC	N. A.	N. A.	Patented	[2]

Drug(s) Targeting Epidermal growth factor receptor (EGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[21]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[6]
Gefitinib	DM15F0X	Solid tumour/cancer	2A00-2F9Z	Approved	[22]
Erlotinib	DMCMBHA	Non-small-cell lung cancer	2C25.Y	Approved	[23]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[24]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[8]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[25]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[24]
Nitroglycerin	DMQ2491	Angina pectoris	BA40	Approved	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[4]
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Inhibitor	[4]
Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1)	TTL7C8Q	IMDH1_HUMAN	Inhibitor	[5] , [2]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.
• [2] Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690.
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008158)
• [4] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [5] VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37.
• [6] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [8] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [9] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [11] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [13] Clinical pipeline report, company report or official report of Roche (2009).
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [16] Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67.
• [17] Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13.
• [18] In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30.
• [19] Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.
• [20] Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther. 2002 Sep;302(3):1272-7.
• [21] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [22] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [23] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [25] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [26] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.